BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1615 related articles for article (PubMed ID: 19016798)

  • 21. Sublingual immunotherapy with a standardised grass pollen extract; a double-blind placebo-controlled study.
    Hordijk GJ; Antvelink JB; Luwema RA
    Allergol Immunopathol (Madr); 1998; 26(5):234-40. PubMed ID: 9885731
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of a short course of specific immunotherapy in patients with allergic rhinoconjunctivitis to ragweed pollen.
    Patel P; Holdich T; Fischer von Weikersthal-Drachenberg KJ; Huber B
    J Allergy Clin Immunol; 2014 Jan; 133(1):121-9.e1-2. PubMed ID: 23870670
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effectiveness of omalizumab in patients with inadequately controlled severe persistent allergic asthma: an open-label study.
    Niven R; Chung KF; Panahloo Z; Blogg M; Ayre G
    Respir Med; 2008 Oct; 102(10):1371-8. PubMed ID: 18657960
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Preventive immunotherapy].
    Boquete M; Carballada F; Expósito F; González A
    Allergol Immunopathol (Madr); 2000; 28(3):89-93. PubMed ID: 10867376
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effects of short-term immunotherapy using molecular standardized grass and rye allergens compared with symptomatic drug treatment on rhinoconjunctivitis symptoms, skin sensitivity, and specific nasal reactivity.
    Klimek L; Mewes T; Wolf H; Hansen I; Schnitker J; Mann WJ
    Otolaryngol Head Neck Surg; 2005 Oct; 133(4):538-43. PubMed ID: 16213926
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis.
    Casale TB; Busse WW; Kline JN; Ballas ZK; Moss MH; Townley RG; Mokhtarani M; Seyfert-Margolis V; Asare A; Bateman K; Deniz Y;
    J Allergy Clin Immunol; 2006 Jan; 117(1):134-40. PubMed ID: 16387596
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunologic effects and tolerability profile of in-season initiation of a standardized-quality grass allergy immunotherapy tablet: a phase III, multicenter, randomized, double-blind, placebo-controlled trial in adults with grass pollen-induced rhinoconjunctivitis.
    Reich K; Gessner C; Kroker A; Schwab JA; Pohl W; Villesen H; Wüstenberg E; Emminger W
    Clin Ther; 2011 Jul; 33(7):828-40. PubMed ID: 21741092
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Grass pollen immunotherapy for seasonal rhinitis and asthma: a randomized, controlled trial.
    Walker SM; Pajno GB; Lima MT; Wilson DR; Durham SR
    J Allergy Clin Immunol; 2001 Jan; 107(1):87-93. PubMed ID: 11149996
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rush sublingual immunotherapy in Parietaria allergic patients.
    D'Ambrosio FP; Ricciardi L; Isola S; Savi E; Parmiani S; Puccinelli P; Musarra A
    Allergol Immunopathol (Madr); 1996; 24(4):146-51. PubMed ID: 8939269
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-effectiveness of specific immunotherapy with Grazax in allergic rhinitis co-existing with asthma.
    Nasser S; Vestenbaek U; Beriot-Mathiot A; Poulsen PB
    Allergy; 2008 Dec; 63(12):1624-9. PubMed ID: 19032235
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sublingual immunotherapy in patients with allergic rhinoconjunctivitis caused by ragweed pollen.
    Skoner D; Gentile D; Bush R; Fasano MB; McLaughlin A; Esch RE
    J Allergy Clin Immunol; 2010 Mar; 125(3):660-6, 666.e1-666.e4. PubMed ID: 20153030
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Effect of 1-year specific immunotherapy with standardized house dust mite vaccine on mild to moderate allergic asthmatic patients].
    Wang HY; Lin XP; Hao CL; Zhang CQ; Sun BQ; Zheng JP; Chen P; Sheng JY; Wu A; Zhong NS
    Zhonghua Jie He He Hu Xi Za Zhi; 2006 Oct; 29(10):679-87. PubMed ID: 17129496
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The role of anti-IgE therapy in combination with allergen specific immunotherapy for seasonal allergic rhinitis.
    Stock P; Rolinck-Werninghaus C; Wahn U; Hamelmann E
    BioDrugs; 2007; 21(6):403-10. PubMed ID: 18020623
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Agreement of efficacy assessments for five-grass pollen sublingual tablet immunotherapy.
    Didier A; Melac M; Montagut A; Lhéritier-Barrand M; Tabar A; Worm M
    Allergy; 2009 Jan; 64(1):166-71. PubMed ID: 19076546
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A randomized, controlled study of specific immunotherapy in monosensitized subjects with seasonal rhinitis: effect on bronchial hyperresponsiveness, sputum inflammatory markers and development of asthma symptoms.
    Crimi N; Li Gotti F; Mangano G; Paolino G; Mastruzzo C; Vancheri C; Lisitano N; Polosa R
    Ann Ital Med Int; 2004; 19(2):98-108. PubMed ID: 15317270
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of combination treatment with anti-IgE plus specific immunotherapy in polysensitized children and adolescents with seasonal allergic rhinitis.
    Kuehr J; Brauburger J; Zielen S; Schauer U; Kamin W; Von Berg A; Leupold W; Bergmann KC; Rolinck-Werninghaus C; Gräve M; Hultsch T; Wahn U
    J Allergy Clin Immunol; 2002 Feb; 109(2):274-80. PubMed ID: 11842297
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of allergen immunotherapy and drug treatment in seasonal rhinoconjunctivitis: a 3-years study.
    Giovannini M; Braccioni F; Sella G; Contoli M; Perri G; Frati F; Incorvaia C
    Eur Ann Allergy Clin Immunol; 2005 Feb; 37(2):69-71. PubMed ID: 15859367
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Additional benefit of a third year of specific grass pollen allergoid immunotherapy in patients with seasonal allergic rhinitis.
    Williams A; Henzgen M; Rajakulasingam K
    Eur Ann Allergy Clin Immunol; 2007 Apr; 39(4):123-6. PubMed ID: 17523386
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Double-blind and placebo-controlled study to assess efficacy and safety of a modified allergen extract of Dermatophagoides pteronyssinus in allergic asthma.
    Ameal A; Vega-Chicote JM; Fernández S; Miranda A; Carmona MJ; Rondón MC; Reina E; García-González JJ
    Allergy; 2005 Sep; 60(9):1178-83. PubMed ID: 16076305
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sustained 3-year efficacy of pre- and coseasonal 5-grass-pollen sublingual immunotherapy tablets in patients with grass pollen-induced rhinoconjunctivitis.
    Didier A; Worm M; Horak F; Sussman G; de Beaumont O; Le Gall M; Melac M; Malling HJ
    J Allergy Clin Immunol; 2011 Sep; 128(3):559-66. PubMed ID: 21802126
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 81.